IDH1 and astrocytoma (excluding glioblastoma): Wefel et al. illustrated that IDH status is valuable for varying NCF in a high-grade astrocytoma cohort (AA and GBM), and patients with IDHwt exhibited worse performances than those with IDHm (9).